Virtual | September 15-17, 2025
MONDAY, SEPTEMBER 15, 2025
8:00 AM – 10:30 AM
SESSION I (PART 1): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
10:30 AM – 1:30 PM
SESSION I (PART 2): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
1:30 PM – 3:00 PM
LUNCH BREAK
3:00 PM – 5:30 PM
PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI-MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT
TUESDAY, SEPTEMBER 16, 2025
8:00 AM – 10:30 AM
SESSION II (PART 1): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
10:30 AM – 1:00 PM
SESSION II (PART 2): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
1:00 PM – 2:00 PM
LUNCH BREAK
2:00 PM – 5:30 PM
SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
WEDNESDAY, SEPTEMBER 17, 2025
8:00 AM – 12:00 PM
SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes
12:00 PM – 1:00 PM
LUNCH BREAK
1:00 PM – 1:40 PM
PANEL ON PRECISION CARE AND HEALTH DISPARITIES IN PROSTATE CANCER
1:40 PM – 2:00 PM
PRESENTATION OF WINNING ABSTRACTS
2:00 PM – 4:00 PM
GENERAL DISCUSSION
4:00 PM
ADJOURN
.8:15 am SESSION I (PART 1): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
Moderators:
Peter Albers, MD, Chairman, Department of Urology, Medical Faculty, Heinrich-Heine-University Düsseldorf and Division Head, Division of Personalized Early Detection of Prostate Cancer at the German Cancer Research Center (DKFZ) Heidelberg, Germany
Sigrid Carlsson, MD, PHD, MPH, Assistant Attending Epidemiologist, Departments of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center and Associate Professor of Experimental Urology, Sahlgrenska Academy, Gothenburg University, Sweden
8:30 am Topic 1: State of the Art and Future Directions in “Smart” Prostate Cancer Screening
8:30 am Topic 1A: Year in Review: Emerging Data and Advances in Screening: Advancing Risk-Stratified Screening and Early Detection
Sigrid Carlsson, MD, PHD, MPH
8:40 am Q & A
8:42 am Topic 1B: Update on the PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50)
Peter Albers, MD
8:52 am Q & A
8:54 am Topic 1C: Updated on the BARCODE1, PROFILE and IMPACT Studies
Jana McHugh, MB, BCh, BAO, Clinical Research Fellow, Institute of Cancer Research and Honorary Senior Registrar in Clinical Oncology, Royal Marsden Hospital, NHS Foundation Trust, London, United Kingdom (TBC)
9:04 am Q & A
9:06 am Topic 1D: Update on PRAISE-U Project – European Union Initiative in PC Screening
Monique Roobol, PhD, Professor of Decision Making in Urology and the Head of the Scientific Research Office, Department of Urology, Erasmus University Medical Centre, Cancer Institute, Rotterdam, The Netherlands
9:16 am Q & A
9:18 am Topic 1E: Organized Prostate Testing (OPT) in Sweden
Anders Bjartell, MD, PhD, FEBU, Professor in Urology, Department of Translational Medicine, Lund University and Senior Consultant, Skane University Hospital, Sweden
9:28 am Q & A
9:30 am – 10:00 am Panel Discussion: “Smart” Prostate Cancer Screening
10:00 am – 10:30 am COFFEE BREAK
10:30 am SESSION I (PART 2): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
Moderators:
Preston Sprenkle, MD, Assistant Professor of Surgery, Yale University School of Medicine; and Member, NCCN Prostate Cancer Early Detection Panel (TBC)
Clare M. C. Tempany, MD, BAO, BCh, Ferenc Jolesz MD Professor of Radiology Harvard Medical School; Vice-Chair, Radiology Research Brigham & Women’s Hospital; Director of the Ferenc Jolesz National Center for Image-Guided Therapy & AMIGO; and Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS Standardization (TBC)
10:30 am Topic 2: Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling
10:30 am Topic 2A: Current and Emerging Molecular and Genetic Diagnostics
10:30 am Overview of Liquid Biomarkers
E. David Crawford, MD, Professor of Urology, University of California San Diego; Chairman, Prostate Conditions Education Council; Editor in Chief, Grand Rounds in Urology; and Prostate Cancer Series Editor, Oncology Journal
10:40 am Q & A
10:42 am – 10:50 am Panel Discussion: Molecular and Genetic Diagnostics
10:50 am Topic 2B: Current and Emerging Imaging Tools and Targeted Biopsies
10:50 am OPTIMUM Trial – A 3-Arm Randomized Controlled Clinical Study Evaluating the Role of Micro-Ultrasound in Men with Clinical Suspicion of Prostate Cancer
Laurence Klotz, MD, Professor of Surgery, University of Toronto and Chair of Prostate Cancer Research, Sunnybrook Medical Center; and Chair, World Urologic Oncology Federation PI-RADS. Sponsored by Exact Imaging.
11:00 am Q & A
11:02 am MRI PI-RADS Standardization and Clinical Evaluation
Clare M. C. Tempany, MB BAO BCh
11:12am Q & A
11:14 am MRI QA
Xavier Golay, PhD, MS, Honorary Professor of MRI Physics, University College London, UK
11:24 am Q & A
11:26 am Topic 3: State of the Art and Future Direction in Prostate Biopsies
11:26 am Topic 3A: Urologic Perspective
Alastair Lamb, MD, PhD, FRCS, CRUK Advanced Clinician Scientist Fellow, Barts Cancer Institute, Queen Mary University of London; Honorary Consultant Urological Surgeon, Guy’s Hospital; and Visiting Associate Professor, University of Oxford, United Kingdom
11:36 pm Q & A
11:38 am Topic 3B: Imaging Perspective
Fergus Coakley, MD, Professor and Chair of Diagnostic Radiology, School of Medicine, Oregon Health and Science University
11:48 pm Q & A
11:50 am Topic 3C: Should we be preparing for a biopsy-free future?
Mark Emberton, MD, Dean, Faculty of Medical Sciences, and Professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London; and Honorary Consultant Urologist, University College London Hospital, United Kingdom
12:00 pm Q & A
12:02 pm – 12:48 pm Panel Discussion: Imaging Modalities and Targeted Biopsies
12:48 pm Topic 4: NCCN Guidelines for Early Detection of Prostate Cancer 2024
Preston Sprenkle, MD (TBC)
12:58 pm Q & A
1:00 pm – 1:30 pm General Discussion
Moderators and Speakers
1:30 pm – 3:00 pm LUNCH BREAK
3:00 pm PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI-MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT
Moderators:
Paul Boutros, PhD, MBA, Director of Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, UCLA
.
Amita Dave, PhD, Vice-Chair, Radiology-Medical Physics Outreach; Deputy Service Chief for Predictive Informatics, and Director of Quantitative Imaging, Department of Radiology, Memorial Sloan Kettering Cancer Center
.
Baris Turkbey, MD, Senior Clinician, Molecular Imaging, Center for Cancer Research, National Cancer Institute, National Institutes of Health (TBC)
.
.
3:00 pm AI And Big Data: What’s Close and What’s Far Away
Paul Boutros, PhD, MBA
3:10 pm Q & A
3:12 pm Integration of Pathology and Genomics for Precision Care of Prostate Cancer
Steven Bova, MD, Emeritus Professor, Personalized Cancer Medicine, Prostate Cancer Research Center, Tampere University, Finland
3:22 pm Q & A
3:24 pm Big Data in Surgery and Computer Vision
Archan Khandekar, MD, Instructor, Desai Sethi Urology Institute, Miller School of Medicine, University of Miami
3:34 pm Q & A
3:36 pm Deep Phenotyping of Prostate Cancer via Multi-Model Imaging and AI to Discover High-Risk Phenotypes
Rakesh Shiradkar, PhD, Assistant Professor, BioHealth Informatics, Indiana University
3:46 pm Q & A
3:48 pm Bioinformatics, AI and Latest Developments in Prostate Cancer Management
Ilya Gipp, MD, PhD, Global Clinical Leader – Oncology, GE Healthcare
3:58 pm Q & A
4:00 pm Digital Healthcare 2025 – Age of Generative AI
KH Rha, MD, PhD, Director, Naver Healthcare Lab, and Clinical Professor of Urology, Yonsei University, South Korea
4:10 pm Q & A
4:12 pm – 5:30 pm Panel Discussion: Moderators, Speakers
8:00 am SESSION II (PART 1): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
Moderators:
Alberto Vargas, MD, Professor and Vice Chair, Department of Radiology, New York University
.
Mohammed Shahait, MBBS, JBU, Consultant of Urology & Robotic Surgery; and Clinical Instructor of Urology at Sharjah University, Fellow of the Endourology Society, and Fellow of the Society of Urology Robotic Surgeons, Dubai, United Arab Emirates; and Jordan
8:00 am Topic 1: Panel on Multiomics of Prostate Cancer
8:00 am Topic 1A: Clinical and Prognostic Implications of MRI Visibility of Prostate Cancer
Alberto Vargas, MD, Professor and Vice Chair, Department of Radiology, New York University
8:10 am Q & A
8:12 am Topic 1B: Urologic Perspective: Genomics and Natural History of MRI Invisible vs Visible Cancers
Laurence Klotz, MD
8:22 am Q & A
8:24 am Topic 1C: Molecular and Multi-Modality Imaging and Radiomics for Visualization and Staging of the Initial and Recurrent Disease
8:24 am Micro-Ultrasound vs. MRI for Biopsy Decision Making and Active Surveillance
Adam Kinnaird, MD, PhD, FRCSC, Frank and Carla Sojonky Chair in Prostate Cancer Research; Assistant Professor, Division of Urology, Department of Surgery; and Adjunct Assistant Professor, Department of Oncology, University of Alberta, Canada
8:34 am Q & A
8:36 am Molecular Imaging
Stefano Fanti, MD, Professor, Department of Medical and Surgical Sciences, Head of Nuclear Medicine, University of Bologna, Italy
.
.
8:46 am Q & A
8:48 am Topic 1D: Gleason Pattern Quantification as a Replacement for Gleason Scoring
Andrew Vickers, PhD, Attending Research Methodologist, Memorial Sloan Kettering Cancer Center
.
8:58 am Q & A
9:00 am Topic 1E: Novel and Emerging Pathological Factors in Localized and Recurrent Prostate Cancer
Gladell P. Paner, MD, Professor of Pathology and Surgery (Urology), and Director of Genitourinary Pathology Service, University of Chicago
.
9:10 am Q & A
9:12 am Topic 1F: Integration of MRI with Histology, Genomics, and Proteomics
Steven Raman, MD, Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of Medicine, UCLA
.
9:22 am Q & A
9:24 am – 9:40 am Panel Discussion: Multiomics – Moderators and Speakers
9:40 am – 10:30 am COFFEE BREAK
10:30 am SESSION II (PART 2): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
Moderators:
Carlos A. Buchpiguel, MD, PhD, Director of Molecular Imaging and Nuclear Medicine Division; and Full Professor, Department of Radiology and Oncology, São Paulo University School of Medicine, São Paulo -SP, Brazil
Matthew R. Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, UCSF (TBC)
Stefano Fanti, MD, Professor and Director, Specialty School of Nuclear Medicine, and Director, Nuclear Medicine Division and PET Unit, Policlinico S. Orsola, University of Bologna, Italy
Raja B. Khauli, MD, Professor of Urology, American University of Beirut Medical Center, Beirut, Lebanon; and Professor of Surgery and Urology, Carle Health, College of Medicine, University of Illinois in Urbana-Champaign
10:30 am Topic 2: Year in Review
10:30 am Emerging Advances in Diagnosis and Treatment
Matthew Cooperberg, MD, MPH (TBC)
10:40 am Q & A
10:42 am Topic 3: Next-Generation Risk Stratification
Alastair Lamb, MD, PhD, FRCS
10:52 am Q & A
10:54 am Topic 4: Clinicopathologic Correlation
Jane Nguyen, MD, PhD, Assistant Professor of Pathology at the Case Western Reserve University/ Lerner College of Medicine; Director of Genitourinary Pathology; Staff Pathologist in the Diagnostics Institute, Department of Pathology and Laboratory Medicine at the Cleveland Clinic
11:04 am Q & A
11:06 am Topic 5: Human-AI Interaction in Prostate Cancer Detection and Diagnosis: Ways to Team Up
Evis Sala, MD, PhD, FRCR, FRCP, Professor of Radiology & Director of Radiology Training Program, Universita Cattolica del Sacro Cuore, Italy
11:16 am Q & A
11:18 am Topic 6: Current Status of External Validation of Inter-Reader Reproducibility for the Prostate Imaging Quality (PI-QUAL)
Liang Wang, MD, PhD, Professor, Attending Radiologist, Vice-Chairman for the Research and Development, Director of Urogenital Imaging, Department of Radiology, Beijing Friendship Hospital Capital Medical University, China
11:28 am Q & A
11:30 am Topic 7: Integration of Precision Diagnosis and Precision Treatment
11:30 am Topic 7A: Integrated Diagnostics (Radiogenomics) for Active Surveillance, Surgical and Radiation Treatment
Sanoj Punnen, MD, Pap Corps Champions for Cancer Research Endowed Chair in Solid Tumor Research, Associate Professor and Vice Chair of Research, Department of Urology Co-Chair of Genitourinary Site Disease Group, Sylvester Comprehensive Cancer Center University of Miami, Miller School of Medicine (TBC)
11:40 am Q & A
11:42 am Topic 7B: Image-Guided, Minimally-Invasive Treatment
11:42 am Emerging Role of Focal Treatment in Patient Management
Bruno Nahar, MD, Associate Professor of Urologic Oncology, Eric and Elizabeth Feder Endowed Chair in Urologic Oncology Research, Desai Sethi Urology Institute, University of Miami Miller School of Medicine
11:52 pm Q & A
11:54 pm Topic 7C: Radiation Treatment
Daniel Y. Song, MD, Professor of Radiation Oncology and Molecular Radiation Sciences, and Co-Director, Prostate Cancer Multi-Disciplinary Clinic, Johns Hopkins University (TBC)
12:04 pm Q & A
12:06 pm Topic 8: Management of High-Risk, Locally Advanced Prostate Cancer
Raja B. Khauli, MD
12:16 pm Q & A
12:18 pm Topic 9: Recurrent Disease
12:18 pm Topic 9A: Biochemical Recurrence
David Einstein, MD, Assistant Professor, Harvard Medical School, and Attending Physician, Beth Israel Deaconess Medical Center Genitourinary Medical Oncology Program
12:28 pm Q & A
12:30 pm Topic 9B: Principles of Focal Salvage Treatment for Radiorecurrent Prostate Cancer – Is it Feasible?
Giancarlo Marra, MD, Consultant Urologist and Assistant Professor, Division of Urology, AOU Citta Della Salute e Della Scienza and University of Turin, Italy
12:40 pm Q & A
12:42 pm – 1:00 pm Panel Discussion: Integration of Precision Diagnosis and Treatment
1:00 pm – 2:00 pm LUNCH BREAK
2:00 pm SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
Moderators:..
Steven Eric Finkelstein, MD, DABR, FACRO, Director of the Center of Advanced Radiation Excellence (CARE); and Director, Radiation Oncology Research, Associated Medical Professionals, Syracuse, NY
Andrei H. Iagaru, MD, Professor of Radiology – Nuclear Medicine Chief, Division of Nuclear Medicine and Molecular Imaging; and Co-Director, PET-MRI Research Program Stanford University
Raluca Mititelu, MD, PhD, Lecturer, University of Medicine and Pharmacy Carol Davila Central University Emergency Military Hospital Bucharest, Romania
2:10 pm Topic 1: Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease
2:10 pm Topic 1A: NCCN Guidelines for Management of Advanced Prostate Cancer
Marc B. Garnick, MD, Director of Cancer Community Services, BIDMC; Gorman Brothers Professor of Medicine at Harvard Medical School; and Editor-in-Chief, Harvard Medical School Prostate Disease Report
2:20 pm Q & A
2:22 pm Topic 1B: Sequencing of Treatment
Arnulf Stenzl, MD, Professor and Chairman, Department of Urology, University of Tuebingen, Germany; Secretary General Adjunct – European Association of Urology; and Member, European Cancer Organization (ECO) Board of Directors
2:32 pm Q & A
2:34 pm Topic 1C: Emerging Advances in Precision Radiation Treatment
Steven E. Finkelstein, MD, DABR, FACRO
2:44 pm Q & A
2:46 pm – 3:10 pm COFFEE BREAK
3:10 pm Topic 1D: Novel Targeted Treatment
3:10 pm Recent Advances and Future Directions in Targeted Treatment
Daniel P. Petrylak, MD, Professor of Medicine and Director of Genitourinary Oncology; and Co-Director of Signal Transduction Program, Yale University
3:20 pm Q & A
3:22 pm Topic 1E: Immunotherapy
Sandy Srinivas, MD, Medical Oncologist, Stanford Health Care; Professor of Medicine (Oncology) and Urology, Stanford University; and Vice Chair, NCCN Panel for Prostate Cancer Treatment
3:32 pm Q & A
3:34 pm – 3:50 pm Panel Discussion: Standard and Emerging Treatment
3:50 pm Topic 2: Molecular Imaging and Theranostics
3:50 pm Topic 2A: Radiopharmaceutical Design and Molecular Imaging
Katherine Ferrara, PhD, Professor and Division Chief, Molecular Imaging Program, Stanford University
4:00 pm Q & A
4:12 pm Q & A
4:14 pm – 4:30 pm Panel Discussion: Molecular Imaging and Theranostics
4:30 pm – 5:30 pm General Discussion: Speakers, Moderators
8:00 am SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes
Moderators:
David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York
Giovanni Lughezzani, MD, Staff Physician, Department of Urology, Humanitas Clinical and Research Hospital, Rozzano (MI), and Associate Professor, Humanitas University, Milan, Italy
Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine
Stephen Zappala, MD, Clinical Assistant Professor, Department of Urology, Tufts University School of Medicine
Stenio Zequi, MD, MSc, PhD, Head of Referral Center for Urological Tumors, A.C. Camargo Cancer Center, Brazil
8:10 am Topic 1: Focal Therapy for Localized Prostate Cancer – Why Hasn’t it Become the Standard of Care?
Rafael Sanchez-Salas, MD, Associate Professor of Surgery and Attending Surgeon, Division of Urology, Department of Surgery, McGill University, Canada
8:20 am Q & A
8:22 am Topic 2: Focal Therapy for Prostate Cancer – How to Choose an Optimal Weapon?
David Margel, MD, PhD, Founder, Rabin Medical Center and BRCA clinic, Member, Early Detection Committee at the Cancer War Society (TBC)
8:32 am Q & A
8:34 am Topic 3: Patient Selection for Focal Therapy – Radiologic Perspective
8:34 am Quantitative MRI Reading, AI Derived Algorithms for ECE/BCR, and AI Use in MRI Directed Treatment of Prostate Cancer
Victoria Bird, MD, Urologic Int. Care, CEO, National Medical Association
8:44 am Q & A
8:46 am Energy Sources and Emerging Clinical Indications
Jurgen Futterer, MD, PhD, Interventional Radiologist, Professor of Image-guided Interventional Oncology, RadboudUMC Nijmegen, The Netherlands; and Professor, Robotics and Mechanics Group, University of Twente, the Netherlands
8:56 am Q & A
8:58 am Multiomics and Patient Selection
John Feller, MD, Chief Medical Officer, HALO Diagnostics; and Assistant Clinical Professor of Radiology, Loma Linda University School of Medicine
9:08 am Q & A
9:10 am Topic 4: Patient Selection for Prostate Cancer Focal Therapy – Urologic Perspective
Geoffrey Sonn, MD, Assistant Professor of Urology and Radiology, Stanford University School of Medicine
9:20 am Q & A
9:22 am Topic 5: Focal Therapy Recurrences and Management
Abhinav Sidana, MD, MPH, Associate Professor of Surgery, Director of Focal Therapy, University of Chicago
9:32 am Q & A
9:34 am – 10:00 am COFFEE BREAK
10:00 am Topic 6: Panel on Addressing Fundamental Challenges in Clinical Acceptance and Adoption of Image-Guided Treatment – Perspective from the AdMeTech Foundation’s International Working Group
10:00 am Review and Update- Post Treatment Assessment and Creating Imaging-Based Short- and Intermediate- Term Patient Outcomes
Faina Shtern, MD
10:10 am Standardized MRI and Molecular Imaging Reporting for Focal Therapy Follow-up
Daniel Margolis, MD, Associate Professor of Radiology, Director, Prostate MRI, and Chair, Weill Cornell Institutional Review Board, Weill Cornell Medical College, Cornell University
10:20 am Q & A
10:22 am Overview of the Current Approaches to Standardized MRI Reporting
Francesco Giganti, MD, PhD, Associate Professor of Radiology, Faculty of Medical Sciences, University College London, Honorary Consultant Radiologist, University College London Hospitals
10:32 am Q & A
10:34 am University of Toronto Experience – MRI After Focal Treatment
Sangeet Ghai, MD, FRCR, Deputy Chief of Research and Associate Professor, Joint Department of Medical Imaging at the University of Toronto, Canada (TBC)
10:44 am Q & A
10:46 am – 11:00 am Panel on MRI Reporting – Recommendations and Discussion
Lead By:
Francesco Giganti, MD;
Daniel Margolis, MD;
Sangeet Ghai, MD;
Panel Members:
Giovanni Lughezzani, MD;
Giancarlo Marra, MD;
Angela Tong, MD, Clinical Assistant Professor, Abdominal Imaging Section, Departments of Radiology and Urology, NYU, and Sadhna Verma, MD, FSAR, Professor of Radiology, University of Cincinnati College of Medicine
11:30 am – 12:00 pm Panel on Molecular Imaging Post Focal Treatment – Emerging Data and Next Steps (TBC)
Irene Burger, MD, Head of Nuclear Medicine, Kantonsspital Baden, Baden Switzerland; Attending Nuclear Medicine, University Hospital Zurich, Switzerland.
Stefano Fanti, MD;
Andrei Iagaru, MD, FACNM
12:00 pm – 1:00 pm LUNCH BREAK
1:00 pm KEYNOTE PRESENTATIONS: Precision Care and Health Disparities in Prostate Cancer – Risk Assessment in Black Men
Keynote Speakers:
Adam B Murphy, MD, MBA, MSCI, Assistant Professor, Department of Urology & Preventive Medicine, Northwestern Medicine – Feinberg School of Medicine, Affiliate Member of Institute for Global Health and Center for Community Health
Faina Shtern, MD
1:15 pm Q & A
1:20 pm Do We Understand the Prostate Cancer Genome?
Paul Boutros, PhD, MBA
1:35 pm Q & A
1:40 pm – 2:00 pm Presentation of Winning Abstracts
2:00 pm – 4:00 pm General Discussion
4:00 pm ADJOURN